Validating the PSOGI classification of peritoneal disease from non-carcinoid epithelial appendiceal neoplasms in the curative and palliative setting: an observational retrospective study.
Appendiceal neoplasm
cytoreductive surgery (CRS)
hyperthermic intraperitoneal chemotherapy (HIPEC)
pathology
pseudomyxoma peritonei (PMP)
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
10
09
2021
accepted:
30
01
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
ppublish
Résumé
Few studies on long-term survival have been published since the new updated pseudomyxoma peritonei (PMP) classification was published in 2016. The aim was to investigate long-term survival according to the Peritoneal Surface Oncology Group International (PSOGI) classification and compare prognostic factors. From Uppsala University Hospital, consecutive patients referred for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from 2004 to 2017 with peritoneal disease from non-carcinoid mucinous epithelial appendiceal neoplasms were included in the study. The peritoneal disease was divided into four groups: mucin only, low-grade mucinous carcinoma peritonei (MCP-1), high-grade (MCP-2), and high-grade with signet ring cells (MCP-3). Survival curves were rendered, and prognostic factors were compared. The study included 223 patients: 36 with mucin only, 112 with MCP-1, 70 with MCP-2, and 5 with MCP-3. Thirty-eight patients had a palliative debulking or open/close procedure. The 5- and 10-year overall survival was 97% and 97% for mucin only, 83% and 70% for MCP-1, 69% and 49% for MCP-2, with no patients still under follow-up after 5 years in the MCP-3 group. In a multivariable analysis, completeness of cytoreduction (CC) score 2-3 and PSOGI class MCP-3 were significantly associated with lower survival. The 5-year overall survival in the palliative setting was 40% The PSOGI classification of PMP provides a solid differentiation of prognostic groups after CRS/HIPEC treatment, but not in the palliative setting.
Sections du résumé
Background
UNASSIGNED
Few studies on long-term survival have been published since the new updated pseudomyxoma peritonei (PMP) classification was published in 2016. The aim was to investigate long-term survival according to the Peritoneal Surface Oncology Group International (PSOGI) classification and compare prognostic factors.
Methods
UNASSIGNED
From Uppsala University Hospital, consecutive patients referred for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from 2004 to 2017 with peritoneal disease from non-carcinoid mucinous epithelial appendiceal neoplasms were included in the study. The peritoneal disease was divided into four groups: mucin only, low-grade mucinous carcinoma peritonei (MCP-1), high-grade (MCP-2), and high-grade with signet ring cells (MCP-3). Survival curves were rendered, and prognostic factors were compared.
Results
UNASSIGNED
The study included 223 patients: 36 with mucin only, 112 with MCP-1, 70 with MCP-2, and 5 with MCP-3. Thirty-eight patients had a palliative debulking or open/close procedure. The 5- and 10-year overall survival was 97% and 97% for mucin only, 83% and 70% for MCP-1, 69% and 49% for MCP-2, with no patients still under follow-up after 5 years in the MCP-3 group. In a multivariable analysis, completeness of cytoreduction (CC) score 2-3 and PSOGI class MCP-3 were significantly associated with lower survival. The 5-year overall survival in the palliative setting was 40%
Conclusions
UNASSIGNED
The PSOGI classification of PMP provides a solid differentiation of prognostic groups after CRS/HIPEC treatment, but not in the palliative setting.
Identifiants
pubmed: 35557579
doi: 10.21037/jgo-21-581
pii: jgo-13-02-859
pmc: PMC9086030
doi:
Types de publication
Journal Article
Langues
eng
Pagination
859-870Informations de copyright
2022 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-21-581/coif). PHC reports unrestricted funding from the Bengt Ihre Fellowship fund which has paid for processing charges and provided time for article drafting. The other authors have no conflicts of interest to declare.
Références
Ann Surg Oncol. 2016 Apr;23(4):1149-56
pubmed: 26577120
Asian J Surg. 2021 Jun;44(6):848-853
pubmed: 33622598
Eur J Surg Oncol. 2016 Jul;42(7):1035-41
pubmed: 27132072
Ann Surg Oncol. 2018 Feb;25(2):404-413
pubmed: 29159742
Eur J Surg Oncol. 2021 Jan;47(1):188-193
pubmed: 33092969
Br J Surg. 2018 May;105(6):668-676
pubmed: 29412465
Am J Surg Pathol. 2016 Jan;40(1):14-26
pubmed: 26492181
Ann Surg Oncol. 2018 Jan;25(1):76-82
pubmed: 29110275
Mod Pathol. 2015 Jan;28 Suppl 1:S67-79
pubmed: 25560600
Adv Anat Pathol. 2018 Jan;25(1):38-60
pubmed: 29016471
J Clin Pathol. 2020 Apr;73(4):220-222
pubmed: 31611287
Ann Surg Oncol. 2021 May;28(5):2819-2827
pubmed: 33471266
Eur J Surg Oncol. 2018 Jul;44(7):1105-1111
pubmed: 29685759
Int Semin Surg Oncol. 2005 Feb 08;2(1):3
pubmed: 15701175
Am J Surg Pathol. 2006 May;30(5):551-9
pubmed: 16699309
Langenbecks Arch Surg. 2018 Dec;403(8):985-990
pubmed: 30506401
Scand J Surg. 2016 Jun;105(2):84-9
pubmed: 26232048
Am J Surg Pathol. 1995 Dec;19(12):1390-408
pubmed: 7503361
Ann Surg. 1994 Feb;219(2):109-11
pubmed: 8129480